BioStock: Improved clinical data and new shareholder strengthen Medivir

Medivir attended the ASCO GI conference recently and presented updated data from the ongoing phase Ib/IIa study with fostrox in advanced hepatocellular carcinoma. The clinical benefit continues to improve as the study progresses and data matures. In the meantime, Medivir has carried out a directed share issue of around SEK 20 million, gaining Hallberg Management as a new strategic shareholder. BioStock spoke with Medivir’s CEO Jens Lindberg to learn more.

Read the interview with Jens Lindberg at biostock.se:

Improved clinical data and new shareholder strengthen Medivir - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/